More than 60% of hospital patients need an intravascular (IV) device to deliver life-saving medical treatment. Yet, one third of IV devices stop working before medical treatment is complete, and patients, families and healthcare institutions bear the physical, emotional and economic costs.
The AVATAR team is committed to eliminating ineffective practices, and to replacing them with innovative solutions, thus improving patient care and saving healthcare costs. We conduct quality, rigorous and clinically focussed research to investigate causes of device failure and to identify and promote proven strategies for prevention. Our research findings are incorporated into clinical practice guidelines, used every day by clinicians and policy makers world-wide, to deliver the best possible care for patients with intravascular devices. But there is more work to be done.
Industry partners play an important role in developing reliable, practical and cost-effective products for the delivery of medical treatment and improving patient care. We work with different commercial industry partners but are affiliated with no one company. Depending on the nature of the research problem, we engage with industry partners in a number of different ways. Our approach is flexible and tailored to the needs of each customer.
Currently, AVATAR's research is supported by several sponsors.
How industry partners can support AVATAR:
Unrestricted research grant or scholarship: While the research or education topic is collaborative, the scope of work is dictated by us, research outcomes are independent and not influenced by the needs of any third party. This aids to the independence of the research during the result dissemination.
Collaborative research: The scope of work is jointly dictated and we provide significant intellectual contribution to the project.
Commercial consultancy and research: The scope of work is dictated by the customer and all intellectual property is owned by the customer.
Please complete this enquiry form and we will be in touch.